FI114141B - Stabila torrpulver - Google Patents
Stabila torrpulver Download PDFInfo
- Publication number
- FI114141B FI114141B FI950282A FI950282A FI114141B FI 114141 B FI114141 B FI 114141B FI 950282 A FI950282 A FI 950282A FI 950282 A FI950282 A FI 950282A FI 114141 B FI114141 B FI 114141B
- Authority
- FI
- Finland
- Prior art keywords
- glu
- gly
- asn
- hirudin
- cys
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Glanulating (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Detergent Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (11)
1. Lyofiliserad farmaceutisk komposition, kännetecknad därav, att den innehäller hirudin och ett vattenlösligt 5 salt av kalcium och/eller magnesium.
2. Komposition enligt patentkravet 1, kännetecknad därav, att det vattenlösliga saltet är kalciumklorid, magne-siumklorid eller magnesiumsulfat. 10
3. Komposition enligt patentkravet 1 eller 2, kännetecknad därav, att molförhällandet kalcium- eller magnesium-joner till hirudin är högst 40:1.
4. Komposition enligt nägot av de föregäende patentkraven, kännetecknad därav, att den ocksä innehäller socker.
5. Komposition enligt patentkravet 4, kännetecknad därav, att sockret är mannitol, trehalos, sackaros, sorbitol, 20 fruktos, glukos, maltos, laktos eller dextran.
\ 6. Komposition enligt nägot av de föregäende patentkraven, kännetecknad därav, att hirudinet är en modifikation av desulfatohirudin eller en mutant därav. • i · 25
7. Komposition enligt nägot av de föregäende patentkraven, . kännetecknad därav, att hirudinet är desulfatohirudin *::: hvi. « · • f ’· ” 30
8. Komposition enligt nägot av de föregäende patentkraven, kännetecknad därav, att den erhälls genom att upplösa ·,: · ingredienserna i vatten, och sedan lyofilisera lösnin- :.‘‘i gen. 114141
9. Komposition enligt patentkravet 8, kännetecknad därav, att lösningens pH före lyofiliseringen är mellan 4 och I 9.
10. Komposition enligt nägot av patentkraven 8-9, känne tecknad därav, att koncentrationen av hirudin i lösnin-gen före lyofiliseringen är 0,1-500 mg/ml.
11. Komposition enligt nägot av patentkraven 8-10, känne-10 tecknad därav, att lösningen före lyofiliseringen är isotonisk. » t » * * » · » * » * » * » * * · · I · | · • » t < » · • * ‘ I * · · • · • · > ' » » t · ! »
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9401448 | 1994-01-26 | ||
| GB9401448A GB9401448D0 (en) | 1994-01-26 | 1994-01-26 | Stable dry powders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI950282A0 FI950282A0 (sv) | 1995-01-23 |
| FI950282A FI950282A (sv) | 1995-07-27 |
| FI114141B true FI114141B (sv) | 2004-08-31 |
Family
ID=10749332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI950282A FI114141B (sv) | 1994-01-26 | 1995-01-23 | Stabila torrpulver |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5733874A (sv) |
| EP (1) | EP0665019B1 (sv) |
| JP (1) | JP3350604B2 (sv) |
| KR (1) | KR100360784B1 (sv) |
| AT (1) | ATE195426T1 (sv) |
| AU (1) | AU701886B2 (sv) |
| CA (1) | CA2140971C (sv) |
| CY (1) | CY2259B1 (sv) |
| DE (1) | DE69518342T2 (sv) |
| DK (1) | DK0665019T3 (sv) |
| ES (1) | ES2151022T3 (sv) |
| FI (1) | FI114141B (sv) |
| GB (1) | GB9401448D0 (sv) |
| GR (1) | GR3034816T3 (sv) |
| HU (1) | HU216628B (sv) |
| IL (1) | IL112389A (sv) |
| NO (1) | NO316883B1 (sv) |
| NZ (1) | NZ270384A (sv) |
| PT (1) | PT665019E (sv) |
| ZA (1) | ZA95576B (sv) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9401447D0 (en) | 1994-01-26 | 1994-03-23 | Ciba Geigy Ag | Pharmaceutical compositions |
| DE19607239A1 (de) | 1996-02-27 | 1997-08-28 | Behringwerke Ag | Pharmazeutische Zusammensetzung, enthaltend Hirudin und Verfahren zu deren Herstellung |
| KR20000070338A (ko) | 1997-01-20 | 2000-11-25 | 나가시마 카쭈시게, 노미야마 아키히코 | 펩티드의 안정화 방법 및 당해 방법을 이용한 펩티드 함유 동결건조 의약조성물 |
| US7795205B2 (en) * | 2004-04-12 | 2010-09-14 | Canyon Pharmaceuticals, Inc. | Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor |
| EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS |
| JP6884858B2 (ja) | 2016-10-21 | 2021-06-09 | アムジエン・インコーポレーテツド | 医薬製剤及びその製造方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1243358B (it) * | 1990-07-23 | 1994-06-10 | Iketon Farmaceutici Srl | Composizioni farmaceutiche per la somministrazione orale di irudina |
| JP2965359B2 (ja) * | 1991-01-07 | 1999-10-18 | 積水化学工業株式会社 | 血液検査用容器 |
| AU659432B2 (en) * | 1991-03-08 | 1995-05-18 | Novartis Ag | A method for the inhibition or prevention of tumor cell metastasis with hirudin |
| GB9303275D0 (en) * | 1993-02-18 | 1993-04-07 | Ciba Geigy Ag | Pharmaceutical compositions |
-
1994
- 1994-01-26 GB GB9401448A patent/GB9401448D0/en active Pending
-
1995
- 1995-01-19 IL IL11238995A patent/IL112389A/xx not_active IP Right Cessation
- 1995-01-20 DE DE69518342T patent/DE69518342T2/de not_active Expired - Lifetime
- 1995-01-20 AU AU11318/95A patent/AU701886B2/en not_active Expired
- 1995-01-20 PT PT95300361T patent/PT665019E/pt unknown
- 1995-01-20 EP EP95300361A patent/EP0665019B1/en not_active Expired - Lifetime
- 1995-01-20 AT AT95300361T patent/ATE195426T1/de active
- 1995-01-20 ES ES95300361T patent/ES2151022T3/es not_active Expired - Lifetime
- 1995-01-20 DK DK95300361T patent/DK0665019T3/da active
- 1995-01-20 JP JP00690595A patent/JP3350604B2/ja not_active Expired - Fee Related
- 1995-01-23 FI FI950282A patent/FI114141B/sv not_active IP Right Cessation
- 1995-01-24 HU HU9500216A patent/HU216628B/hu unknown
- 1995-01-24 NZ NZ270384A patent/NZ270384A/en not_active IP Right Cessation
- 1995-01-24 CA CA002140971A patent/CA2140971C/en not_active Expired - Lifetime
- 1995-01-25 ZA ZA95576A patent/ZA95576B/xx unknown
- 1995-01-25 NO NO19950274A patent/NO316883B1/no not_active IP Right Cessation
- 1995-01-25 KR KR1019950001264A patent/KR100360784B1/ko not_active IP Right Cessation
- 1995-01-25 US US08/378,225 patent/US5733874A/en not_active Expired - Lifetime
-
2000
- 2000-11-10 GR GR20000402503T patent/GR3034816T3/el unknown
-
2002
- 2002-01-18 CY CY0200008A patent/CY2259B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI950282A (sv) | 1995-07-27 |
| HU216628B (hu) | 1999-07-28 |
| GR3034816T3 (en) | 2001-02-28 |
| DE69518342T2 (de) | 2001-02-01 |
| KR100360784B1 (ko) | 2003-02-25 |
| NO950274D0 (no) | 1995-01-25 |
| AU1131895A (en) | 1995-08-03 |
| NO950274L (no) | 1995-07-27 |
| ZA95576B (en) | 1995-07-26 |
| HU9500216D0 (en) | 1995-03-28 |
| US5733874A (en) | 1998-03-31 |
| JP3350604B2 (ja) | 2002-11-25 |
| DE69518342D1 (de) | 2000-09-21 |
| DK0665019T3 (da) | 2000-10-30 |
| IL112389A0 (en) | 1995-03-30 |
| ATE195426T1 (de) | 2000-09-15 |
| NZ270384A (en) | 1996-02-27 |
| ES2151022T3 (es) | 2000-12-16 |
| CA2140971A1 (en) | 1995-07-27 |
| PT665019E (pt) | 2001-01-31 |
| JPH07267877A (ja) | 1995-10-17 |
| CA2140971C (en) | 2008-11-25 |
| HUT70474A (en) | 1995-10-30 |
| EP0665019A1 (en) | 1995-08-02 |
| AU701886B2 (en) | 1999-02-11 |
| NO316883B1 (no) | 2004-06-28 |
| CY2259B1 (en) | 2003-07-04 |
| KR950031105A (ko) | 1995-12-18 |
| IL112389A (en) | 2003-05-29 |
| EP0665019B1 (en) | 2000-08-16 |
| GB9401448D0 (en) | 1994-03-23 |
| FI950282A0 (sv) | 1995-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6025467A (en) | Parathyroid hormone derivatives and their use | |
| KR20010032881A (ko) | 안정한 테리파라타이드 용액 | |
| US5965536A (en) | Methods of inhibiting CXC intercrine molecules | |
| FI114141B (sv) | Stabila torrpulver | |
| HU205773B (en) | Process for producing new human insulin derivativ and pharmaceutical compositions comprising same as active ingredient | |
| CZ20004525A3 (cs) | Analogy inzulínu, způsob jejich přípravy a farmaceutické přípravky obsahující tyto analogy | |
| US20240299552A1 (en) | Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists | |
| Orlowski et al. | Biologically potent analogues of salmon calcitonin which do not contain an N‐terminal disulfide‐bridged ring structure | |
| EP0758905B1 (en) | Pharmaceutical compositions comprising hirudin | |
| MXPA96003010A (en) | Pharmaceutical compositions | |
| US5472938A (en) | Pharmaceutical depot compositions containing hirudin | |
| US20240024425A1 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| US7094880B2 (en) | Decorin proteoglycan inhibitor of fibrinogen blood clotting | |
| AU685079B2 (en) | Peptide inhibitors of CXC intercrine molecules | |
| CA2026776A1 (en) | Stabilized, potent grf analogs | |
| CA2092906A1 (en) | Stabilized, potent grf analogs | |
| CA2178927A1 (en) | Peptide inhibitors of cxc intercrine molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or assigment of application |
Owner name: NOVARTIS AG |
|
| MA | Patent expired |